Phages for treatment of Klebsiella pneumoniae infections.

Klebsiella pneumoniae is an opportunistic pathogen involved in both hospital- and community-acquired infections. K. pneumoniae is associated with various infections, including pneumonia, septicemia, meningitis, urinary tract infection, and surgical wound infection. K. pneumoniae possesses serious virulence, biofilm formation ability, and severe resistance to many antibiotics especially hospital-acquired strains, due to excessive use in healthcare systems. This limits the available effective antibiotics that can be used for patients suffering from K. pneumoniae infections; therefore, alternative treatments are urgently needed. Bacteriophages (for short, phages) are prokaryotic viruses capable of infecting, replicating, and then lysing (lytic phages) the bacterial host. Phage therapy exhibited great potential for treating multidrug-resistant bacterial infections comprising K. pneumoniae. Hence, this chapter emphasizes and summarizes the research articles in the PubMed database from 1948 until the 15th of December 2022, addressing phage therapy against K. pneumoniae. The chapter provides an overview of K. pneumoniae phages covering different aspects, including phage isolation, different morphotypes of isolated phages, in vitro characterization, anti-biofilm activity, various therapeutic forms, in vivo research and clinical studies.

New formula of the green synthesised Au@Ag core@shell nanoparticles using propolis extract presented high antibacterial and anticancer activity.

Antimicrobial alternatives such as nanoparticles are critically required to tackle bacterial infections, especially with the emerging threat of antibiotic resistance. Therefore, this study aimed to biosynthesize Au-Ag nanoparticles using propolis as a natural reducing agent and investigate their antibacterial activity against antibiotic-resistant Staphylococcus sciuri (S. sciuri), Pseudomonas aeruginosa (P. aeruginosa), and Salmonella enterica Typhimurium (S. enterica), besides demonstrating their anticancer activity in cancer cell lines. The biosynthesized Au@AgNPs were characterized using UV-Vis spectrophotometer, Transmission Electron Microscopy (TEM), Zeta potential, Dynamic Light Scattering (DLS), Fourier Transformation Infrared (FTIR), and Scanning Electron Microscopy (SEM). Moreover, the detection of antibacterial activity was assessed through disc diffusion, the Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC), time-killing curve, and detection of cell membrane integrity via SEM. As a result, the UV-Vis spectrum revealed the formation of Au@AgNPs in a single peak between 533 and 555 nm. Furthermore, FTIR analysis confirmed nanoparticles' green synthesis due to the presence of carbon functional groups. The formulated Au@AgNPs showed antibacterial activity against both Gram-positive and Gram-negative bacteria. The MIC and the MBC of P. aeruginosa and S. sciuri were 31.25 µg/mL. However, nanoparticles were more effective on S. enterica with MIC of 7.5 µg/mL and MBC of 15.6 µg/mL. Furthermore, the time-killing curve of the three model bacteria with the treatment was effective at 50 µg/mL. Besides, SEM of the tested bacteria indicated unintegrated bacterial cell membranes and damage caused by Au@AgNPs. Regarding the anticancer activity, the results indicated that the biosynthesized Au@AgNPs have a cytotoxic effect on HEPG2 cell lines. In conclusion, this research revealed that the green synthesized Au@AgNPs could be effective antibacterial agents against S. sciuri, P. aeruginosa, and S. enterica and anticancer agents against HEPG2.